Ⓐ
PeptiBrief
Evidence Library
randomized_clinical_trial · 2021

Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial

Pellesi L|Al-Karagholi MAM|Chaudhry BA|Snellman J|Hannibal J|Amin FM|Ashina M · JAMA Network Open
strongPMID · 34357396Trial · nct04260035Verified
View source
Plain-English summary

A two-hour VIP infusion caused migraine attacks in susceptible participants, confirming powerful human vascular and sensory activity.

Population
Adults with migraine
Intervention
Intravenous VIP or placebo
Outcomes measured
Migraine attack|Headache intensity|Vascular measures|Adverse effects
Key findings
Demonstrated that prolonged VIP exposure can provoke migraine.
Limitations
Provocation model|Small specialist sample|Not a therapeutic efficacy trial
Risk of bias
Moderate; randomized design but specialist provocation endpoint.
Citation
Pellesi L|Al-Karagholi MAM|Chaudhry BA|Snellman J|Hannibal J|Amin FM|Ashina M (2021). Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Network Open
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.